Be the first to like this
IntroductionThe Parkinson's disease market is approaching maturity, with the threat of generic incursion evident in each drug class. Although growth will be stifled by generic launches, relatively successful lifecycle management strategies and new product launches see the Parkinson's disease market grow at a compound annual growth rate (CAGR) of 2.6% over the next 10 years (20082018).Scope*In-depth analysis of the current and future Parkinson's disease market across the US, Japan, France, Germany, Italy, Spain and the UK.*Parkinson's disease-specific sales forecasts for brands and generics from 2008 to 2018.*Assessment of the leading Parkinson's disease brands and drug classes to identify key success factors within this market.*Evaluation of the strategies of leading players in the Parkinson's disease market.HighlightsStalevo's clear convenience and compliance benefit will see the combination therapy emerge as the market leading brand between 2011 and 2013.Although Boehringer Ingelheim is relatively late to the market with a once-daily reformulation, Mirapex/Sifrol's (pramipexole) dominant share of some geographic markets will facilitate a successful launch in 2010.Over the 10-year forecast period the US market will lose significance for Parkinson's disease market players as demographic changes and a less competitive commercial environment will see the European and Japanese markets emerge as key generators of growth.Reasons to Purchase*Quantify the performance of each of the marketed Parkinson's disease drugs in the seven major markets over the period 2008 to 2018.*Assess the changing key opportunities and threats affecting current market players and prospective new entrants.*Identify the leading brands in this market over the next 10 years and understand the key factors driving their success.